RxDoctor Payments Data

Christopher Byard, MD

Cardiovascular Disease · Dothan, ALNPI 1730173535

Payments from drug & device makers

$5,441in general payments, 2019–2025

Across 358 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$790
  • Novartis$638
  • Amarin Pharma, Inc.$635
  • Pfizer$559
  • Amgen$545
  • E.r. Squibb & Sons, L.L.C.$445
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$5,441100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,441 in reported general payments places this provider in the 60th percentile of 292 cardiovascular disease providers in Alabama.

See all cardiovascular disease providers in Alabama

Medicare billing

Part B allowed, 2024
$77,656
Medicare patients
374
Services billed
1,802

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban308$336,618
XareltoRivaroxaban117$132,369
EntrestoSacubitril/Valsartan121$124,315
Repatha SureclickEvolocumab44$43,614
MultaqDronedarone Hcl29$41,577
JardianceEmpagliflozin35$33,403
Nebivolol Hcl434$28,876
FarxigaDapagliflozin Propanediol16$16,691
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide261$13,199
Nifedipine ErNifedipine362$10,709
Valsartan285$9,090
VascepaIcosapent Ethyl24$8,264
Ezetimibe271$6,411
Prasugrel Hcl22$5,962
Dabigatran EtexilateDabigatran Etexilate Mesylate14$4,170

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$559$336,618308 claims
Johnson & JohnsonXarelto$302$132,369117 claims
NovartisEntresto$638$124,315121 claims
Sanofi-aventis U.S. LLCMultaq$154$41,57729 claims
Boehringer IngelheimJardiance$285$33,40335 claims
AstraZenecaFarxiga$790$16,69116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 292 cardiovascular disease providers in Alabama.

Other cardiovascular disease in Dothan

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →